Drug repositioning
HPV
cervical cancer
drug repurposing
host-oriented drugs
host-pathogen protein-protein interactions
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
11
2022
accepted:
06
01
2023
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
epublish
Résumé
Integrating interaction data with biological knowledge can be a critical approach for drug development or drug repurposing. In this context, host-pathogen-protein-protein interaction (HP-PPI) networks are useful instrument to uncover the phenomena underlying therapeutic effects in infectious diseases, including cervical cancer, which is almost exclusively due to human papillomavirus (HPV) infections. Cervical cancer is one of the second leading causes of death, and HPV16 and HPV18 are the most common subtypes worldwide. Given the limitations of traditionally used virus-directed drug therapies for infectious diseases and, at the same time, recent cancer statistics for cervical cancer cases, the need for innovative treatments becomes clear. Accordingly, in this study, we emphasize the potential of host proteins as drug targets and identify promising host protein candidates for cervical cancer by considering potential differences between HPV subtypes (i.e., HPV16 and HPV18) within a novel bioinformatics framework that we have developed. Subsequently, subtype-specific HP-PPI networks were constructed to obtain host proteins. Using this framework, we next selected biologically significant host proteins. Using these prominent host proteins, we performed drug repurposing analysis. Finally, by following our framework we identify the most promising host-oriented drug candidates for cervical cancer. As a result of this framework, we discovered both previously associated and novel drug candidates, including interferon alfacon-1, pimecrolimus, and hyaluronan specifically for HPV16 and HPV18 subtypes, respectively. Consequently, with this study, we have provided valuable data for further experimental and clinical efforts and presented a novel bioinformatics framework that can be applied to any infectious disease.
Identifiants
pubmed: 36761959
doi: 10.3389/fonc.2023.1096081
pmc: PMC9905826
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1096081Informations de copyright
Copyright © 2023 Kori, Turanli and Arga.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Protoc. 2007;2(10):2366-82
pubmed: 17947979
OMICS. 2022 Jul;26(7):392-403
pubmed: 35763314
Cancer Res. 2007 Nov 1;67(21):10163-72
pubmed: 17974957
PLoS One. 2014 May 30;9(5):e97842
pubmed: 24879114
Biochim Biophys Acta Gen Subj. 2019 May;1863(5):903-916
pubmed: 30825616
J Proteome Res. 2021 Feb 5;20(2):1107-1132
pubmed: 33426872
Gynecol Oncol. 2020 Oct;159(1):150-156
pubmed: 32723675
Mol Cancer Ther. 2012 Oct;11(10):2265-73
pubmed: 22821149
Onco Targets Ther. 2020 May 18;13:4239-4247
pubmed: 32547058
Gynecol Oncol. 2013 Aug;130(2):269-74
pubmed: 23672928
Saudi J Biol Sci. 2019 Sep;26(6):1146-1153
pubmed: 31516343
Turk J Biol. 2021 Apr 20;45(2):138-148
pubmed: 33907496
Exp Ther Med. 2019 Sep;18(3):1823-1830
pubmed: 31410143
Onco Targets Ther. 2020 Feb 28;13:1845-1849
pubmed: 32184619
Pharmacology. 2018;101(5-6):322-329
pubmed: 29621762
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374121
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Nat Commun. 2019 Mar 13;10(1):1197
pubmed: 30867426
Biology (Basel). 2021 Aug 18;10(8):
pubmed: 34440026
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
Gynecol Oncol Rep. 2019 Nov 21;31:100520
pubmed: 31867435
Immunobiology. 2020 Nov;225(6):152008
pubmed: 33130519
J Cheminform. 2020 Jul 22;12(1):46
pubmed: 33431024
Sci Rep. 2020 May 26;10(1):8719
pubmed: 32457456
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
J Cancer Sci Ther. 2009 Nov 30;1(2):52-61
pubmed: 20505783
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
J Clin Oncol. 2010 Aug 1;28(22):3562-9
pubmed: 20606083
Bioinformatics. 2013 May 15;29(10):1357-8
pubmed: 23515528
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
OMICS. 2017 Oct;21(10):584-591
pubmed: 29049014
Curr Top Med Chem. 2018;18(12):1007-1014
pubmed: 30101711
PLoS One. 2018 Jul 18;13(7):e0200717
pubmed: 30020984
Cancer Chemother Pharmacol. 2016 Jul;78(1):101-9
pubmed: 27206639
BMC Cancer. 2017 Jun 8;17(1):407
pubmed: 28595616
Cancer Res. 2007 May 15;67(10):4605-19
pubmed: 17510386
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Genome Med. 2014 Nov 29;6(11):115
pubmed: 25593595
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Arch Biochem Biophys. 2022 Jan 15;715:109085
pubmed: 34800440
PLoS One. 2013;8(2):e55975
pubmed: 23405241
Drug Deliv. 2005 Nov-Dec;12(6):327-42
pubmed: 16253949
Cancer. 2014 Apr 15;120(8):1187-93
pubmed: 24615735
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Invest New Drugs. 2017 Dec;35(6):800-812
pubmed: 28864978
Brief Bioinform. 2021 Mar 22;22(2):1206-1214
pubmed: 32914167
Drugs. 2001;61(11):1661-91
pubmed: 11577799
J Eur Acad Dermatol Venereol. 2003 Sep;17(5):493-503
pubmed: 12941081
Circ Cardiovasc Genet. 2014 Aug;7(4):536-47
pubmed: 25140061
Lancet Glob Health. 2022 Aug;10(8):e1115-e1127
pubmed: 35839811
Am J Transl Res. 2019 Sep 15;11(9):5404-5416
pubmed: 31632519
Bioinformatics. 2003 Jan 22;19(2):185-93
pubmed: 12538238
Genes Chromosomes Cancer. 2008 Sep;47(9):755-65
pubmed: 18506748
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165885
pubmed: 32574835